Back to Massachusetts

H4495 • 2025

An Act to protect 340B providers

An Act to protect 340B providers

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor
Financial Services (J)
Last action
2026-03-19
Official status
Referred to Joint Committee on Health Care Financing
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act to protect 340B providers

An Act to protect 340B providers Status: Referred to Joint Committee on Health Care Financing

What This Bill Does

  • An Act to protect 340B providers Status: Referred to Joint Committee on Health Care Financing

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-03-19 House

    Reporting date extended to Monday, June 15, 2026

  2. 2025-12-08 House

    Reporting date extended to Wednesday, March 18, 2026

  3. 2025-09-18 House

    Reported from the committee on Financial Services

  4. 2025-09-18 House

    New draft of H1296

  5. 2025-09-18 House

    Reported favorably by committee and referred to the committee on Health Care Financing

Official Summary Text

An Act to protect 340B providers
Status:
Referred to Joint Committee on Health Care Financing

Current Bill Text

Read the full stored bill text
×

Bill H.4495

SECTION 1. Chapter 176O of the General Laws is hereby amended by adding the following section:-

Section 31. (a) In this section “340B covered entity” means an entity participating in the federal 340B drug discount program, as described in 42 U.S.C. § 256b, including its pharmacy or pharmacies, or any pharmacy or pharmacies, contracted with the participating entity to dispense drugs purchased through such program. (b) A pharmacy benefit manager or other third party that reimburses a 340B covered entity for drugs shall not:

(1) reimburse the 340B covered entity for a drug at a rate lower than that paid for the same drug to entities that are not 340B covered entities; (2) assess any fee, charge-back, or other adjustment on the 340B covered entity on the basis that the covered entity participates in the 340B program; (3) restrict participation in a pharmacy or provider network based on an entity’s status as a 340B covered entity; (4) require the 340B covered entity to enter into a contract with a specific pharmacy to participate in the pharmacy benefit manager or third party’s pharmacy or provider network; (5) require a claim for a drug to include a modifier, supplemental transmission, to indicate that the drug is a 340B drug, or any other method of identifying the claim for a 340B drug, unless the claim is for payment, directly or indirectly, by Medicaid; or (6) impose coverage or benefits limitations, or require an enrollee to pay an additional fee, higher copay, higher coinsurance, second copay, second coinsurance, or other penalty when obtaining a drug from a 340 covered entity; (7) interfere with the patient's right to choose to obtain a drug from a 340B covered entity, including inducement, steering, or offering financial or other incentives.

The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

Close